NY-CONDECO
12.4.2022 14:32:04 CEST | Business Wire | Press release
Condeco , a global leader in workspace scheduling software, is today announcing the launch of its new marketing campaign that is uniquely designed to address the immediate need for businesses to redefine the workplace and respond to the evolving expectations of their employees.
Condeco’s campaign will debut with a new film short that showcases the needs of the modern workplace and contextualizes the new wave of business culture that is turning the traditional office environment on its head. Positioned as a satirical comedy, the film short highlights the growing generational divide that has emerged out of the pandemic, and light-heartedly cements the importance of having an employer that understands and embraces employee needs.
In addition to the launch of this new film, Condeco’s new marketing campaign includes a new consumer report that supports the importance of fostering a workplace that respects the desires of its employees, with hybrid work opportunities at its core. As full-time remote work becomes a pandemic pastime, this report’s findings underscore the need for business leaders to prioritize employee happiness, mental health, and digital technology as they adopt hybrid work models.
“It’s no secret that there has been a seismic shift in how we work” said Lynda Lowe, CMO at Condeco. “Work is now an outcome that is no longer defined by a single physical location and there is a growing tension point between business leaders who are trying to force a return to the office and their employees who want to be able to work flexibly. But this does not mean that leaders should discount the value of the office altogether. Instead, leaders must understand the value of the office has shifted to providing a safe space for employee collaboration. The past two years have taught us that empowering employees with time and space to do this at their choosing is key to supporting their mental health and well-being, as well as driving enhanced business culture and social interaction.”
Condeco’s new marketing campaign follows the brand’s repositioning in 2021 , which recognized the immediate need for employers to provide their employees with the flexibility to work from anywhere. Delivering on its mission to help businesses redefine their workplace, Condeco acquired ProxyClick in January 2022 to expand Condeco’s workspace solutions for the enterprise, enabling the company to drive an end-to-end employee and guest experience with the connected office – and ultimately, help businesses prepare for the future at work.
Condeco’s new film will air across connected TV and social channels starting on Tuesday, April 12, 2022. Media planned and bought by Hubble , part of What’s Possible Group. The film was produced by Arts & Sciences and directed by Casey Storm, who is known for his work with brands including Paypal, Apple, Hulu, Expedia, and more.
To view the full broadcast, please see here: https://youtu.be/HunkSOvLJ4M . To learn more about Condeco’s new report on hybrid work, please see here .
About Condeco
Condeco is the global leader in enterprise level workspace solutions. Our software is designed to equip everyone with the tools they need for a seamless end to end experience in today’s office. By giving people control over flexible work, we deliver the certainty people need, enable the collaboration teams crave, and facilitate the insights on capacity that employers demand. From visitor management to workspace booking to office optimization, we are trusted by over 2000 of the world’s largest companies to realize their future at work.
About Arts & Sciences
Arts & Sciences was started over a decade ago as a boutique production company that specializes in producing award-winning advertising content, music videos, fine art projects, original documentaries, and feature films. Located in Los Angeles, NYC, and London, Arts & Sciences represents a diverse group of top directors and creators and has been named a Creativity A-List Production Company five times. Every major advertising award show has recognized its work, including Cannes Lions, Clio, AICP, D&AD, The One Show, and the Andys. Their original content work has been featured in the New Frontiers showcase at the Sundance Film Festival, The New Yorker, Nowness, and Purple Magazine. Arts & Sciences has produced work for every major global brand, such as Google, Apple, Facebook, Nike, AT&T, Samsung, Volkswagen, Ford, Toyota, American Express, MLB, the NFL, and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005251/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
